These findings describe a novel pathway for the regulation of SERT activity and 5HT inactivation, and therefore may provide a new route to the development of medications for the treatment of both brain 5HT-related disorders (such as major depression, OCD, anxiety and autism) and blood 5HT-related disorders (such as coronary heart disease). The work of these Vanderbilt researchers identifies a means of modulating SERT activity through its protein-protein interactions, as opposed to recognition of 5HT targeted by current SSRI, and therefore may regulate the transporter without compromising normal SERT function.

Supplemental Documents
VU07144—Integrin Beta3 as a Target for the Modulation of Serotonergic Signaling

Inventors
Randy Blakely
Ana Carneiro


CONTACT
Karen Rufus
(615) 322-4295
karen.rufus@vanderbilt.edu

File Number: MKT07144